NASDAQ:RUBY - Rubius Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Rubius Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.68 +0.22 (+2.60 %) (As of 02/23/2020 04:00 PM ET) Add Compare Today's Range$8.26Now: $8.68▼$8.7950-Day Range$7.70MA: $8.57▼$9.8452-Week Range$6.96Now: $8.68▼$20.04Volume167,558 shsAverage Volume212,916 shsMarket Capitalization$692.66 millionP/E RatioN/ADividend YieldN/ABeta2.31 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RUBY Previous Symbol CUSIPN/A CIKN/A Webhttp://www.rubiustx.com/ Phone617-679-9600Debt Debt-to-Equity Ratio0.30 Current Ratio9.83 Quick Ratio9.83Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.97 per share Price / Book1.75Profitability EPS (Most Recent Fiscal Year)($2.27) Net Income$-89,190,000.00 Net MarginsN/A Return on Equity-41.30% Return on Assets-32.65%Miscellaneous Employees142 Outstanding Shares79,800,000Market Cap$692.66 million Next Earnings Date3/26/2020 (Estimated) OptionableNot Optionable Receive RUBY News and Ratings via Email Sign-up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:RUBY Rates by TradingView Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions What is Rubius Therapeutics' stock symbol? Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY." How were Rubius Therapeutics' earnings last quarter? Rubius Therapeutics Inc (NASDAQ:RUBY) announced its earnings results on Thursday, November, 14th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by $0.06. During the same quarter in the previous year, the business posted ($0.42) earnings per share. View Rubius Therapeutics' Earnings History. When is Rubius Therapeutics' next earnings date? Rubius Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Rubius Therapeutics. What price target have analysts set for RUBY? 4 analysts have issued 12 month price objectives for Rubius Therapeutics' shares. Their forecasts range from $4.00 to $40.00. On average, they anticipate Rubius Therapeutics' share price to reach $19.50 in the next year. This suggests a possible upside of 124.7% from the stock's current price. View Analyst Price Targets for Rubius Therapeutics. What is the consensus analysts' recommendation for Rubius Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Rubius Therapeutics. What are Wall Street analysts saying about Rubius Therapeutics stock? Here are some recent quotes from research analysts about Rubius Therapeutics stock: 1. According to Zacks Investment Research, "Rubius Therapeutics, Inc. is a bio-technology company. It develops cellular therapies for the treatment of auto-immune, metabolic and other diseases. Rubius Therapeutics, Inc. is based in Cambridge, United States. " (2/5/2020) 2. HC Wainwright analysts commented, "We have currently only assigned value to RTX-134 in PKU and RTX-240 in NSCLC. Our price target of $40/share is based on an equally-weighted composite of: (a) $40.7/share, as a 30x multiple of taxed and diluted $21.95 discounted back to FY19 at 20% (in line with the expected P/E multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $39.4/share (discounted cash flow analysis using a 20% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (6/26/2019) Has Rubius Therapeutics been receiving favorable news coverage? News coverage about RUBY stock has been trending very positive on Sunday, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Rubius Therapeutics earned a coverage optimism score of 4.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Rubius Therapeutics. Who are some of Rubius Therapeutics' key competitors? Some companies that are related to Rubius Therapeutics include Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC), Regenxbio (RGNX), Bill.com (RVMD), Cortexyme (CRTX), Coherus Biosciences (CHRS), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Beam Therapeutics (BEAM), I-Mab (BDTX), NanoString Technologies (NSTG), Orchard Therapeutics (ORTX), BAVARIAN NORDIC/S (BVNRY) and Twist Bioscience (TWST). What other stocks do shareholders of Rubius Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rubius Therapeutics investors own include Sorrento Therapeutics (SRNE), Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Marinus Pharmaceuticals (MRNS), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Aclaris Therapeutics (ACRS) and Adverum Biotechnologies (ADVM). Who are Rubius Therapeutics' key executives? Rubius Therapeutics' management team includes the folowing people: Mr. David R. Epstein, Exec. Chairman (Age 57)Dr. Christopher L. Carpenter M.D., Ph.D., Chief Medical Officer (Age 63)Dr. Pablo J. Cagnoni, CEO, Pres & Director (Age 56)Mr. Andrew M. Oh, Chief Financial Officer (Age 47)Ms. Joanne M. Protano, Sr. VP of Fin. & Operations (Age 50) When did Rubius Therapeutics IPO? (RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO. Who are Rubius Therapeutics' major shareholders? Rubius Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (11.49%), Capital World Investors (6.49%), Baillie Gifford & Co. (5.33%), Sumitomo Mitsui Trust Holdings Inc. (1.80%), Nikko Asset Management Americas Inc. (1.80%) and Janus Henderson Group PLC (0.94%). Company insiders that own Rubius Therapeutics stock include Christopher L Carpenter, Francis M Cuss, Robert Langer and Torben Straight Nissen. View Institutional Ownership Trends for Rubius Therapeutics. Which major investors are selling Rubius Therapeutics stock? RUBY stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., ARK Investment Management LLC, Janus Henderson Group PLC, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Bank of America Corp DE, New York State Common Retirement Fund and Credit Suisse AG. Company insiders that have sold Rubius Therapeutics company stock in the last year include Christopher L Carpenter, Robert Langer and Torben Straight Nissen. View Insider Buying and Selling for Rubius Therapeutics. Which major investors are buying Rubius Therapeutics stock? RUBY stock was bought by a variety of institutional investors in the last quarter, including Capital World Investors, FMR LLC, Abbot Financial Management Inc., EcoR1 Capital LLC, Alpine Global Management LLC, State Street Corp, Trexquant Investment LP and UBS Group AG. View Insider Buying and Selling for Rubius Therapeutics. How do I buy shares of Rubius Therapeutics? Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Rubius Therapeutics' stock price today? One share of RUBY stock can currently be purchased for approximately $8.68. How big of a company is Rubius Therapeutics? Rubius Therapeutics has a market capitalization of $692.66 million. The company earns $-89,190,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis. Rubius Therapeutics employs 142 workers across the globe.View Additional Information About Rubius Therapeutics. What is Rubius Therapeutics' official website? The official website for Rubius Therapeutics is http://www.rubiustx.com/. How can I contact Rubius Therapeutics? Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected] MarketBeat Community Rating for Rubius Therapeutics (NASDAQ RUBY)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 147 (Vote Outperform)Underperform Votes: 173 (Vote Underperform)Total Votes: 320MarketBeat's community ratings are surveys of what our community members think about Rubius Therapeutics and other stocks. Vote "Outperform" if you believe RUBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RUBY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2020 by MarketBeat.com StaffFeatured Article: What member countries make up the G-20?
